Objectives: Penicillin-susceptible Staphylococcus aureus isolates account for a fifth of cases of S. aureus bacteraemia (SAB) in Denmark, but little is known about treatment outcomes with penicillins or other antimicrobials. Here we compare penicillin, dicloxacillin and cefuroxime as definitive treatments in relation to 30 day mortality.
Introduction
A fifth of invasive cases of Staphylococcus aureus bacteraemia (SAB) in Denmark remain susceptible to penicillin and the drug of choice for treatment of penicillin-susceptible S. aureus is penicillin. 1 This recommendation is based on in vitro data that indicate a superior potency of penicillin over penicillinase-resistant b-lactams. 2 However, observational studies or randomized trials to support the recommendation have not been performed.
Several recent studies have questioned the effectiveness of the antimicrobials frequently used in the treatment of methicillin-susceptible SAB. Paul et al. 3 showed a comparable efficacy of cefazolin and cloxacillin, whereas other b-lactams, including second-and third-generation cephalosporins, were associated with a higher mortality. Similarly, Schweizer et al. 4 reported significantly lower mortality hazards associated with cefazolin and nafcillin than with vancomycin.
Evidence from randomized clinical trials comparing different antimicrobials for the treatment of infectious diseases is scarce. While randomized trials are central to the collection of efficacy data, these are unlikely to be conducted for off-patent drugs. In non-randomized studies, the investigator has no control over the treatment assignment, and direct comparisons of the treatment groups may be misleading owing to bias. In the setting of observational data and case series, propensityscore adjustment and matching is a method of reducing the bias between treatment groups. 5, 6 The propensity score for an individual is the probability of receiving a given treatment based on the individual's covariate values. Using the score to match and adjust balances the unequal chance of allocation to a treatment group.
We hypothesized that the treatment of penicillin-susceptible SAB with penicillin would lead to improved survival compared with treatment with other antimicrobials.
Methods

Study setting
We conducted a retrospective case series review of consecutive adult (≥16 years) patients with penicillin-susceptible SAB in six hospitals served by three departments of clinical microbiology (DCMs) 
Susceptibility testing
Antimicrobial susceptibility testing was carried out initially at the DCMs using disc diffusion and the clover-leaf test. All blood culture isolates of S. aureus were routinely referred to the national reference laboratory (Statens Serum Institut, Copenhagen) and retested using disc diffusion, according to the EUCAST guideline, i.e. an inoculum with a turbidity equivalent to that of a 0.5 McFarland standard on Mueller -Hinton agar using a 1 U penicillin disc. After 18 -22 h of incubation at 358C, the zone sizes were read with callipers and the zone edge was inspected. Susceptibility was defined as a zone size ≥26 mm and a fuzzy zone edge. 2 
Data variables
Data extracted from medical charts included age, sex, the origin of the bacteraemia, (community, hospital, healthcare associated or unknown), 7, 8 the site of infection associated with the SAB (the primary focus), possible secondary manifestations, injection drug use (IDU), plasma creatinine level (the highest recorded value within 24 h of blood culture), antimicrobial therapy (duration, dose and route of administration) and vital status at day 30.
The Pitt bacteraemia score is a severity of illness grading system evaluating mental status, the presence or absence of fever, hypotension, mechanical ventilation and cardiac status for each patient within the time period of 2 days before and 1 day after the first positive blood culture. 9, 10 Data on co-morbidity were collected from the National Patient Registry (NPR) 11 and used to calculate the Charlson Comorbidity Index (CCI). 12 We calculated the CCI score by gathering diagnoses from the NPR from up to 10 years prior to the date of SAB and excluding other diagnoses from the admission with SAB. Diagnosis codes in the NPR were coded by physicians at hospital discharge according to the International Classification of Diseases, 8th revision (ICD-8), until the end of 1993 and according to the ICD-10 thereafter.
Time to death (in days) was calculated from the day the first positive blood culture was obtained.
Definitions
Case definitions
Patients above 15 years of age with confirmed penicillinsusceptible SAB were eligible for inclusion.
Empirical antimicrobial treatment
Empirical treatment was defined as any antimicrobial agent administered between the time the blood culture was obtained and the time of the final blood culture result (i.e. identification of S. aureus and its susceptibility pattern). Appropriate empirical antimicrobial therapy had to meet the following criteria: the administration of at least one antimicrobial to which the isolate was susceptible in vitro, and initiation of therapy within 2 days of blood culture.
Definitive antimicrobial treatment
Definitive treatment was defined as antimicrobial therapy administered after the results of the susceptibility testing had become available and initiated no later than 5 days after blood culture. Definitive treatment was categorized as penicillin, dicloxacillin, cefuroxime or other. Cases treated with penicillin, dicloxacillin and cefuroxime received only that antimicrobial.
Optimal doses were defined as daily dosing with at least 1.2 g of benzylpenicillin every 8 h, 1 g of dicloxacillin every 6 h or 0.75 g of cefuroxime every 8 h. 2 
Combination antimicrobial therapy
Cases receiving more than one antimicrobial agent as the initial treatment were categorized as being treated with combination antimicrobial therapy. The additional antimicrobial drugs were fusidic acid, an aminoglycoside, ciprofloxacin, rifampicin, a macrolide or other.
Statistics
All values are presented as medians and IQRs. Categorical variables were compared using x 2 statistics. Annual data were divided into three periods (1995 -2000, 2001-05 and 2006 -10) to assess changes with time.
Cox proportional hazards models were used to compute hazard ratios (HRs) and 95% CIs. The proportional hazards assumption was checked either visually for categorical variables or by Schoenfeld residuals for numerical variables. A test for interaction was performed and interaction terms fitted accordingly by multiplying the two factors. In univariate analysis, all variables were tested for their association with 30 day mortality. Variables with associations at P,0.10 were included in the multivariate analysis. We compared survival times using the log-rank test and presented these as Kaplan -Meier curves. ORs with 95% CIs were computed by conditional logistic regression analysis.
We employed propensity score methods, in which the predicted probability of treatment with cefuroxime was derived from unconditional logistic regression, utilizing a manual backward-elimination approach. The predicted probability of the model was used as the propensity score for each patient. For the propensity-score-matched case -control study, patients in the cefuroxime treatment group were matched with patients in the penicillin treatment group who had the closest propensity scores within a calliper size of one-quarter of the standard deviation of the propensity score. Thus, we excluded cases in which the propensity score difference was more than 0.038. Thirty day mortality was compared between the propensity-score-matched groups. The goodness of fit of the model was tested with the Hosmer -Lemeshow test, 13 which revealed an adequate model fit (P ¼ 0.72). Data were analysed using IBM SPSS Statistics (version 20; IBM, Armonk, New York, USA).
Results
A total of 795 consecutive patients with penicillin-susceptible SAB were identified. Of these, 207 cases were excluded because of age ,16 years (n ¼16), undeterminable definitive antimicrobial therapy (n¼ 74), lack of antimicrobial therapy (n¼ 18), an ambiguous susceptibility pattern (n ¼15), unavailability of a blood culture isolate for confirmatory penicillin susceptibility testing (n¼ 28), death within the first 3 days after the blood culture had been obtained, i.e. prior to reaching the point at which definitive antimicrobial therapy could be received, as per the definition above (n¼ 52), and oral antimicrobial therapy (n¼ 4). Thus, a total of 588 cases were included in the final analysis.
Antimicrobial treatment
As shown in Table 1 , penicillin was the most frequently used single agent for definitive antimicrobial therapy, followed by dicloxacillin and cefuroxime. Thirty-nine per cent of patients received either another agent or combination therapy. Ninetytwo per cent started empirical treatment within 1 day of blood culture. A total of 77% and 93% of patients had initiated definitive treatment within 3 and 4 days of blood culture, respectively. Penicillin was used more often in cases with a high Pitt bacteraemia score, community-acquired SAB from Aalborg Hospital, cases with active IDU or cases with a secondary manifestation of endocarditis or meningitis. Cases from Herlev, with a primary focus associated with an intravascular device or dialysis, were more often treated with dicloxacillin. Cases with a primary focus of respiratory infection or an unknown focus were more often treated with cefuroxime.
Among the patients treated with penicillin, 159 of 166 (96%) were optimally dosed. The unadjusted mortality in the penicillin group receiving optimal dosing was 21%, compared with 0% for the seven patients who received suboptimal treatment. In the dicloxacillin group, 61 of 111 (55%) patients were treated with an optimal dose, 42 (38%) with a suboptimal dose and 8 (7%) with an unknown dose. The unadjusted mortality in these groups was 11%, 7% and 25%, respectively. In patients treated with cefuroxime, 80 of 85 (94%) received an optimal dose, three (3.5%) a suboptimal dose and two (2.5%) an unknown dose. The unadjusted mortality was 40%, 33% and 50%, respectively.
Survival
Of the 588 individuals, 121 died within 30 days (20.6%). Survival curve analysis indicated an increased mortality rate associated with cefuroxime at day 30 compared with the other antimicrobials (Figure 1 ; log-rank test P¼ 0.001).
By univariate regression analysis, definitive antimicrobial treatment with cefuroxime compared with penicillin was associated with an increased risk of death at 30 days. Older age, a higher Pitt score and a primary focus of respiratory infection, other foci or an unknown focus were also associated with an increased risk of death. Definitive antimicrobial therapy with dicloxacillin, active IDU, hospital-acquired SAB and osteomyelitis/ arthritis were associated with a decreased risk of death (Table 2 ). Initial treatment, initial combination therapy, inappropriate initial treatment or CCI was not associated with a change in mortality.
The propensity score was derived from an unconditional logistic regression model controlling for age, sex, origin, CCI, primary focus, secondary manifestation, Pitt score, IDU, plasma creatinine, hospital and year. There were interactions between time period and IDU, secondary manifestation and hospital; between hospital and IDU and primary focus; and between origin and age, Pitt score, IDU, primary focus, secondary manifestation and hospital. Terms for each interaction were included in the regression model. Use of cefuroxime for definitive treatment was more likely for women, patients with an unknown origin and a date of 2001 onwards compared with 1995-2000, and was less likely at Amager, Herlev, Glostrup and Aalborg Hospitals compared with Hvidovre Hospital (Table S1 , available as Supplementary data at JAC Online).
In multivariate analysis, all the variables associated with outcome at P,0.1 in the univariate analysis were included and further adjusted for the propensity score. There were interactions between origin and age, Pitt score, IDU and secondary manifestations; between IDU and Pitt score; and between definitive antimicrobial and time. Terms for each interaction were included in the multivariate model. Cefuroxime as the definitive antimicrobial therapy remained significantly associated with a risk of death compared with treatment with penicillin (HR 2.68, 95% CI 1.50-4.78).
A high Pitt score, a primary focus in the lung and 'focus other or unknown' remained independently associated with an increased risk of death. Without propensity-score adjustment, the HR of the association of cefuroxime and mortality was reduced to 2.00 (95% CI 1.16-3.15) ( Table 3) .
Regression models with dicloxacillin-treated patients as the reference yielded similar estimates of survival. Without and with propensity-score adjustment, the HRs of 30 day mortality were 4.71 (95% CI 2.44-9.09) and 3.44 (95% CI 1.67 -7.11), respectively, for cefuroxime-treated compared with dicloxacillintreated patients. There was no difference in risk of death Nissen et al. (17) 35 (14) 113 (45) associated with the use of penicillin or other treatments when compared with dicloxacillin.
Propensity-score-matched case -control study
Fifty-six patients in the cefuroxime treatment group were matched with the 56 patients in the penicillin treatment group who had the closest propensity scores (Table S2, available as Supplementary data at JAC Online). The 27 cefuroxime-treated patients who were excluded because they could not be matched to a penicillin-treated patient did not differ with respect to age, sex, origin, CCI, primary focus, secondary manifestation, Pitt score, IDU, plasma creatinine level, hospital or year. The clinical characteristics and demographic data of the patients included were comparable in the matched group (Table 4) . Twenty-two patients (39%) in the matched cefuroxime group and 11 patients (20%) in the matched penicillin group died within 30 days [OR 2.65 (95% CI 1.13-6.19), P ¼ 0.025]. Three patients were suboptimally dosed with either penicillin or cefuroxime. Removal of the data for these three patient pairs did not affect the result. Among the recipients of cefuroxime, 22 of 53 (42%) died, compared with 10 of the 53 recipients of penicillin (19%) (P ¼0.019). Similarly, we matched 45 patients in the cefuroxime treatment group with 45 patients in the dicloxacillin treatment group by propensity score (Table S2 , available as Supplementary data at JAC Online). Seventeen patients (38%) in the cefuroxime group died within 30 days compared with seven in the dicloxacillin group (16%), corresponding to an OR of 3.30 (95% CI 1.21 -9.02, P ¼ 0.02). The two groups did not differ with regard to age, sex, CCI, origin, primary focus, secondary manifestation, IDU or Pitt score. Twenty-three patients were suboptimally dosed with dicloxacillin or cefuroxime. After removing these patients' data, the mortality rates were compared but the difference was no longer statistically significant [two of 22 (9%) dicloxacillin-treated patients died compared with seven of 22 (32%) cefuroxime-treated patients; P ¼ 0.13].
Subgroup analyses
In subgroup multivariate analysis, cefuroxime as definitive therapy compared with penicillin remained associated with death for patients with (HR 24.14, 95% CI 1.44 -464.65) or without (HR 2.01, 95% CI 1.14-3.54) a respiratory focus.
Individuals with low and high Pitt scores had an increased risk of 30 day mortality. With a Pitt score .3, the HR for cefuroxime Nissen et al.
compared with penicillin was 4.27 (95% CI 1.14-16.05), whereas with a Pitt score of 0 -3, the HR was 2.81 (95% CI 1.50-5.28).
Discussion
This propensity-score-adjusted and -matched case-control study showed that treating penicillin-susceptible SAB with cefuroxime led to poorer short-term outcomes compared with treatment with either penicillin or dicloxacillin. To our knowledge, such an association has never been reported before for penicillinsusceptible SAB.
A major potential bias of our study is confounding by indication, i.e. that physicians may tend to use cefuroxime for more serious infections due to a perception of its broader coverage despite microbiological identification of the causative microorganism and its antimicrobial susceptibility profile. Using propensity scores to adjust for a skewed use of cefuroxime, penicillin and dicloxacillin can reduce this bias by balancing covariates in the different treatment groups. Our analyses showed that the HR of death was largely unchanged when adjusted or not adjusted for the propensity score (2.46 versus 1.92). Our matched case -control study showed an OR for 30 day mortality of 2.71 -5.16 when cefuroxime treatment was given compared with penicillin or dicloxacillin. None of the other covariates differed between treatment groups after propensity score matching. Furthermore, we used stratified analyses to reduce bias. An analysis of patients with more severe disease showed that the effect estimate was unchanged by stratification. This was true in two situations that may affect physician prescribing: a high Pitt score and a pulmonary focus. This indicates that our results are robust, and we believe the differences in treatment outcomes suggest that penicillin or an antistaphylococcal penicillin is the drug of choice for the treatment of penicillinsusceptible SAB. Further studies are required to determine whether this is also the case for non-bacteraemic infections caused by penicillin-susceptible S. aureus. Our study also warrants a clinical trial to confirm our findings in a controlled setting.
The mechanistic basis for the difference in efficacy of cefuroxime and penicillins is unknown. The inoculum effect, i.e. that specific S. aureus strains produce large amounts of b-lactamase(s), has been suggested to be the basis of clinical failure in patients suffering high-burden staphylococcal disease such as endocarditis. Cephalosporins are generally resistant to b-lactamases but may be hydrolysed by specific types. However, in vitro data indicate that this is not the case for cefuroxime.
14 Another possible explanation could relate to changes in penicillin-binding proteins (PBPs). One strategy to induce resistance to b-lactam antibiotics includes the alteration of endogenous PBPs by point mutations or homologous recombination. 15 Sequencing of PBP1, PBP2 or PBP3 among S. aureus treatment failures may determine whether mutations exist that have a differential effect on penicillin and cefuroxime leading to different affinities of the two b-lactams for PBPs. Therapy of penicillin-susceptible S. aureus A third option is differences in the pharmacokinetic and pharmacodynamic activity of the different antimicrobials. The optimal time for plasma drug concentrations to remain above the MIC has been estimated to be 40% for penicillins and 50% for cephalosporins. 16 With estimated mean MICs for penicillinsusceptible S. aureus of 0.032 mg/L for benzylpenicillin, 0.125 mg/L for dicloxacillin and 1 mg/L for cefuroxime, and based on pharmacokinetic data for the three antimicrobials, 17 the free non-protein-bound plasma drug concentration time . MIC would be roughly 50% for cefuroxime dosing with 1.5 g every 8 h, but ,40% for dosing with 750 mg every 8 h, 67% for dicloxacillin (dosing with 1 g every 6 h) and 100% for benzylpenicillin (dosing with 1.2 g every 8 h). This indicates that cefuroxime carries the greatest risk of falling short of the optimal pharmacokinetic/pharmacodynamic parameter. However, crude survival rates did not differ for individuals dosed below or at these levels, and therefore other unknown mechanisms may be in play.
To our knowledge, our study is the first to address a differential effect of antimicrobial choice on the outcome of bacteraemia with penicillin-susceptible S. aureus. Interestingly, in a recent study from Israel, second-and third-generation cephalosporins were associated with a poorer outcome for methicillinsusceptible SAB in comparison with cefazolin. 3 Our study is limited by a small sample size; in particular, a subset of individuals was included in the case-control studies. Furthermore, treatment groups were assigned retrospectively. Nevertheless, two different methodologies have demonstrated comparable increases in the risk of death associated with treatment with cefuroxime. Clinical inferences from our study should, however, be made with caution until a randomized clinical trial has been performed.
In conclusion, we have shown that the treatment of penicillinsusceptible SAB with cefuroxime compared with penicillin or dicloxacillin was associated with a significantly higher mortality. A clinical trial comparing the two treatments is warranted. Studies are also needed to determine whether this is a class effect for cephalosporins or whether it relates specifically to cefuroxime.
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